Pulmozyme Resource Center: Supporting you and your patients throughout cystic fibrosis (CF) treatment.
At Genentech, we're committed to providing information designed to help you help your patients. The following resources were developed to support the appropriate use of Pulmozyme.
For any questions, contact us at [email protected], by phone at 877-946-5348, or review the User Guide above.
Indication and Usage
Pulmozyme (dornase alfa) is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function.
In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
Important Safety Information
- Patients 5 to 17 years of age: A randomized, placebo-controlled trial of 303 of clinically stable cystic fibrosis patients 5 to 17 years of age who received Pulmozyme
- Patients less than 5 years: Extrapolation of efficacy data in patients 5 years of age and older with additional safety data in 65 pediatric patients aged 3 months to less than 5 years who received Pulmozyme 2.5 mg daily by inhalation for 2 weeks.
You may also report side effects to Genentech at 1-888-835-2555.